AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15870437
Drug: Dose-dense ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense ICE chemotherapy (4-week interval)
Trial: 15870437
Drug: Standard ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ICE chemotherapy (2-week interval)
Trial: 8694724
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% ketorolac tromethamine
Trial: 8694724
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% diclofenac sodium
Trial: 1723467
Drug: Nitrendipine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine, 20 mg b.i.d.
Trial: 1723467
Drug: Nitrendipine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine, 20 mg once daily
Trial: 31851556
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) in combination with intensive induction and consolidation therapy
Trial: 21346613
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (up to 12 weeks)
Trial: 11506099
Drug: Metaraminol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaraminol infusion starting at 0.25 mg/min
Trial: 11506099
Drug: Ephedrine infusion
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine infusion starting at 5 mg/min
Trial: 28856661
Drug: Silk garments
RxNorm normalized name: SILK
DrugBank: Bombyx mori fiber (DB10609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silk garments for the treatment of eczema
Trial: 27271870
Drug: Massed mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massed mental practice (60 min of MP during a single daily session)
Trial: 24385079
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (dose A: 3 injections of 2 U in 0.05 mL of normal saline per injection)
Trial: 24385079
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (dose B: 3 injections of 4 U in 0.05 mL of normal saline per injection)
Trial: 24385079
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (both doses)
Trial: 10386821
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate (100 mg IM, weekly) + LNG 125 microg by mouth, daily
Trial: 10386821
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate (100 mg IM, weekly) + LNG 250 microg by mouth, daily
Trial: 10386821
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate (100 mg IM, weekly) + LNG 500 microg by mouth, daily
Trial: 10386821
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate (100 mg IM, weekly) + Placebo LNG
Trial: 1505563
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg b.i.d. and 20 mg b.i.d. combined
Trial: 6360754
Drug: HBIG (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG (0.5 ml at birth, three months, and six months)
Trial: 6360754
Drug: HBIG (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG (1.0 ml at birth only)
Trial: 26313450
Drug: ranirestat 40
RxNorm normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranirestat 40 mg/day
Trial: 26313450
Drug: ranirestat 80
RxNorm normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranirestat 80 mg/day
Trial: 21420107
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with red light and skin contact
Trial: 21420107
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with red light without skin contact
Trial: 10642965
Drug: Daily membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily membrane sweeping (group II)
Trial: 10642965
Drug: Daily dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dinoprostone (Cervidil) vaginal inserts (group I)
Trial: 9032861
Drug: Gamma Knife
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma Knife radiosurgery with marginal dose of 25-30 Gy
Trial: 1505293
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 mg/kg/day)
Trial: 6429876
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate (20 mg) and ethinylestradiol (0.04 mg)
Trial: 30035582
Drug: #Tamojunto intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: #Tamojunto intervention (12 weekly classes)
Trial: 27128613
Drug: MF/F‐MDI (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F‐MDI (mometasone furoate 800 µg and formoterol fumarate 20 µg)
Trial: 27128613
Drug: MF‐DPI (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF‐DPI (mometasone furoate 800 µg)
Trial: 19617580
Drug: Nonspecific factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific factors (e.g., patient expectations, therapeutic alliances)
Trial: 2338028
Drug: Non-lacquered tablet
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-lacquered tablet (M 250 mg, P 25 mg, S 500 mg)
Trial: 2338028
Drug: Lacquered tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacquered tablets (M 125 mg, P 12.5 mg, S 250 mg)
Trial: 28444456
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (3.0 g/day post-training)
Trial: 19700947
Drug: Prazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (mean dose: 5.7 ± 0.9 mg/day)
Trial: 19700947
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean dose: 5.6 ± 1.2 mg/day)
Trial: 12163794
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol sedation (1-4 mg x kg(‐1) x hr(‐1))
Trial: 7772482
Drug: Inert gel
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert gel base
Trial: 2185611
Drug: Computerized administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computerized administration of SMAST‐13
Trial: 2185611
Drug: Paper-and-pencil administration
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil administration of SMAST‐13
Trial: 2185611
Drug: Computerized administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computerized administration of CAGE
Trial: 2185611
Drug: Paper-and-pencil administration
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil administration of CAGE
Trial: 2185611
Drug: Computerized administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computerized administration of quantity-frequency scale
Trial: 2185611
Drug: Paper-and-pencil administration
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil administration of quantity-frequency scale
Trial: 378509
Drug: Ticrynafen (TCN)
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticrynafen (TCN) 125 mg daily
Trial: 378509
Drug: Probenecid (PBC)
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probenecid (PBC) 500 or 1,000 mg daily
Trial: 27692638
Drug: Lorcaserin extended-release
RxNorm normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin extended-release 20-mg once-daily
Trial: 27692638
Drug: Lorcaserin extended-release
RxNorm normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin extended-release under fed conditions
Trial: 27692638
Drug: Lorcaserin extended-release
RxNorm normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin extended-release under fasted conditions
Trial: 27692638
Drug: Lorcaserin immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin immediate-release 10-mg BID
Trial: 24488700
Drug: SSRIs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs treatment
Trial: 25642918
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neuroendocrine factors, clinical characteristics, and gene polymorphisms
Trial: 23998714
Drug: CRT (Cardiac-resynchronization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT (Cardiac-resynchronization therapy)
Trial: 7541916
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin‐6 (IL‐6) at doses of 0, 1, 2.5, or 5 micrograms/kg/d subcutaneously on days 4 to 13
Trial: 7541916
Drug: Granulocyte colony‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L
Trial: 7541916
Drug: Ifosfamide 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, carboplatin 350 mg/m2 intravenously on day 1 only, and etoposide 75 mg/m2 intravenously on days 1, 2, and 3
Trial: 27064
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of propranolol
Trial: 27064
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with propranolol
Trial: 30223023
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 single injection (6 mL)
Trial: 28341759
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg daily) in Cohort R (R1)
Trial: 28341759
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg every 12 hours) in Cohort NR (NR1)
Trial: 28341759
Drug: Ritonavir (CYP3A4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (CYP3A4 inhibitor)
Trial: 26667367
Drug: Eicosapentaenoic Acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic Acid (EPA) at 1,800 mg/day
Trial: 19647862
Drug: 300-IR SLIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-IR SLIT tablets
Trial: 14712427
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menatetrenone, 45 mg/d)
Trial: 7645443
Drug: Reactivating occupational
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactivating occupational therapy in addition to functional rehabilitation
Trial: 29241395
Drug: Oxytocin (OT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OT) administration
Trial: 29090986
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure therapy (NPT) following cesarean section
Trial: 27626390
Drug: The Incredible
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Incredible Years School Age Program (12 weekly 2-hour sessions)
Trial: 19374795
Drug: Argatroban 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 0.02 mg kg(‐1) h(‐1)
Trial: 19374795
Drug: Argatroban 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 0.04 mg kg(‐1) h(‐1)
Trial: 19374795
Drug: Argatroban 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 0.06 mg kg(‐1) h(‐1)
Trial: 15136383
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 microg daily for 21 days)
Trial: 11291825
Drug: Manual tracking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual tracking task using a hand-held stylus over a digitizing tablet
Trial: 9108186
Drug: Pediatric formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric formulation of ciprofloxacin (125 mg per capsule)
Trial: 9108186
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tablets of ciprofloxacin
Trial: 8275921
Drug: Medifoxamine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medifoxamine (daily dose of 194 mg at day 28)
Trial: 8275921
Drug: Imipramine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (daily dose of 161 mg at day 28)
Trial: 2873890
Drug: ACVP (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACVP (doxorubicin, cyclophosphamide, and prednisolone in combination with vincristine)
Trial: 2873890
Drug: ACTP (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTP (doxorubicin, cyclophosphamide, and prednisolone in combination with teniposide)
Trial: 2873890
Drug: ACTVP (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTVP (doxorubicin, cyclophosphamide, and prednisolone in combination with both vincristine and teniposide)
Trial: 29368152
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) followed by sentinel lymph node biopsy (SNB)
Trial: 22377563
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg daily for 28 days followed by 14 days off (arm 1)
Trial: 22377563
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg daily continuously (arm 2)
Trial: 18714110
Drug: Enhanced intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced intervention (pharmacist case manager providing admission medication verification, medication teaching, discharge counseling, faxing discharge care plan, follow-up phone call)
Trial: 16555577
Drug: Efonidipine (T‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine (T‐ and L‐type Ca2+ channel blocker)
Trial: 16555577
Drug: Nifedipine (L‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (L‐type Ca2+ channel blocker)
Trial: 12472980
Drug: Topical ibuprofen
RxNorm normalized name: ibuprofen Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ibuprofen gel (Ibugel) 5% applied for at least 7 days
Trial: 12472980
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 400 mg tablets (1200 mg daily) taken for at least 7 days
Trial: 12472980
Drug: Topical ibuprofen
RxNorm normalized name: ibuprofen Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ibuprofen gel (Ibugel) 5%
Trial: 12472980
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 400 mg tablets (1200 mg daily)
Trial: 1778334
Drug: Lederle-Takeda APDT
RxNorm normalized name: Pinus taeda pollen
DrugBank: Pinus taeda pollen (DB10744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle-Takeda APDT vaccine
Trial: 1778334
Drug: Lederle DTP
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle DTP vaccine
Trial: 1778334
Drug: Takeda APDT
RxNorm normalized name: Pinus taeda pollen
DrugBank: Pinus taeda pollen (DB10744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Takeda APDT vaccine
Trial: 6168837
Drug: Perhexiline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perhexiline (100 mg twice daily)
Trial: 31977740
Drug: Wireless oral
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless oral patient-controlled analgesia device for the delivery of oxycodone
Trial: 31977740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving PRN oxycodone from nursing staff
Trial: 31088856
Drug: Genetic predisposition
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic predisposition to higher fasting insulin
Trial: 19576082
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy scheme executed at day 1 and day 8 for 6 ‐ 8 cycles
Trial: 19576082
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy scheme executed at day 1 and day 15 for 6 ‐ 8 cycles
Trial: 17381927
Drug: Weekly vitamin
RxNorm normalized name: Ezy Dose Weekly Vitamin Planner 2XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vitamin A supplementation
Trial: 12540224
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg)
Trial: 15041582
Drug: Control (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Vitamin C, 500 mg)
Trial: 11697443
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (68 mg M-3-G)
Trial: 11697443
Drug: Dealcoholized red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dealcoholized red wine (58 mg M-3-G)
Trial: 11697443
Drug: Red grape
RxNorm normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red grape juice (117 mg M-3-G)
Trial: 9129483
Drug: Regular milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular milk (240 mL)
Trial: 9129483
Drug: Lactose-hydrolyzed milk
RxNorm normalized name: MILK PROTEIN,HYDROLYZED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-hydrolyzed milk (240 mL)
Trial: 8199724
Drug: Felodipine (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (extended release) 5-20 mg
Trial: 8199724
Drug: Enalapril 5-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5-20 mg
Trial: 8199724
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of felodipine and enalapril
Trial: 31971474
Drug: Local heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local heat therapy (HT) applied to one thigh (garment perfused with water at 52°C) for 8 consecutive weeks (90 min, 5 days/wk)
Trial: 31971474
Drug: Control thigh
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control thigh (no treatment)
Trial: 31157554
Drug: Body lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body lipid (g/100g bodyweight)
Trial: 25476120
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use assessments
Trial: 24070632
Drug: 1% chlorhexidine-75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine-75% alcohol solution for cutaneous antisepsis
Trial: 15522126
Drug: Toast with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toast with butter (17.5 g fat)
Trial: 15522126
Drug: Cereal with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal with full-fat milk (17.5 g fat)
Trial: 15522126
Drug: Cereal with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal with semi-skimmed milk (2.7 g fat)
Trial: 15522126
Drug: Water (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (0 g fat)
Trial: 2573768
Drug: Subcutaneous catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous catheter tunnelling (group B)
Trial: 1102987
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily)
Trial: 19713092
Drug: Seal oil
RxNorm normalized name: seal oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal oil (SO), 10mL x 3 daily for 10 days
Trial: 19713092
Drug: Whale oil
RxNorm normalized name: castor oil fish whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whale oil (WO), 10mL x 3 daily for 10 days
Trial: 9768370
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone once daily for 12 weeks